Wan Wei-Na, Zhang Yi-Xia, Wang Xue-Mei, Liu Yan-Jun, Zhang Yu-Qin, Que Yan-Hong, Zhao Wen-Jing
Department of Ultrasound, First Affiliated Hospital of China Medical University, Shenyang, Liaoning E-mail :
Asian Pac J Cancer Prev. 2014;15(6):2777-83. doi: 10.7314/apjcp.2014.15.6.2777.
The purpose of this study was to explore the expression of ATAD2 in ovarian tumor tissue as well as its relationship with degree of malignancy. Tumor tissue from 110 cases of ovarian cancer was collected in accordance with the Declaration of Helsinki for evaluation of ATAD2 expression immunohistochemistry, quantitative PCR (qPCR) and Western blotting. The correlation between the ATAD2 expression and and the prognosis of ovarian cancer was evaluated by Cox regression model. In addition, HO-8910 and OVCAR-3 cells were transfected with two siRNAs targeting ATAD2. Cell viability was evaluated with MTT assay, and cell migration by transwell migration assay. ATAD2 was shown to be highly expressed in 65.5% (72/110) of ovarian cancer cases, both at transcriptional and protein levels. Moreover, highly expression was positively correlated with degree of malignancy. Knock-down of ATAD2 in HO-8910 and OVCAR-3 cells was found to reduce cell migration. In addition, follow-up visits of the patients demonstrated that the 5-year survival rate was lower in patients with high expression of ATAD2. Our study suggested that ovarian tumor tissue may have highly expressed ATAD2, which is associated with tumor stage, omentum-metastasis, ascites and CA-125. Increased ATAD2 may play important roles in tumor proliferation and migration. ATAD2 could serve in particular as a prognostic marker and a therapeutic target for ovarian cancer.
本研究旨在探讨ATAD2在卵巢肿瘤组织中的表达及其与恶性程度的关系。按照《赫尔辛基宣言》收集110例卵巢癌患者的肿瘤组织，采用免疫组织化学、定量聚合酶链反应（qPCR）及蛋白质免疫印迹法评估ATAD2表达。通过Cox回归模型评估ATAD2表达与卵巢癌预后的相关性。此外，用两种靶向ATAD2的小干扰RNA（siRNA）转染HO-8910和OVCAR-3细胞。采用MTT法评估细胞活力，用Transwell迁移试验评估细胞迁移能力。结果显示，65.5%（72/110）的卵巢癌病例中ATAD2在转录和蛋白水平均高表达。而且，高表达与恶性程度呈正相关。敲低HO-8910和OVCAR-3细胞中的ATAD2可降低细胞迁移能力。此外，对患者的随访表明，ATAD2高表达患者的5年生存率较低。我们的研究提示，卵巢肿瘤组织中ATAD2可能高表达，这与肿瘤分期、大网膜转移、腹水及CA-125有关。ATAD2表达增加可能在肿瘤增殖和迁移中起重要作用。ATAD2尤其可作为卵巢癌的预后标志物和治疗靶点。
